Plus Therapeutics
PSTVClinical Pipeline
Program / Asset
Target Indications
Development Phase
Financial Statements & Analysis
Total Gross Revenue
$1.39M $1.40M $5.21M $1.03M
Cost of Revenue / Sales
— — — —
Gross Profit
— — — —
OPERATING EXPENSES
2025-06-302025-09-302025-12-312026-03-31
Research & Development (R&D)
($1.25M) ($2.44M) ($8.38M) ($2.87M)
Selling & Marketing Expense
— — — —
General & Administrative (G&A)
($1.68M) ($3.44M) ($12.13M) ($5.28M)
Operating Income / (Loss)
($1.54M) ($4.48M) ($15.30M) ($7.12M)
NON-OPERATING & FINANCING ITEMS
2025-06-302025-09-302025-12-312026-03-31
Interest Income / Cash Yields
$0.03M $0.06M $0.12M $0.19M
Interest & Debt Servicing Expense
($0.55M) ($0.55M) ($0.55M) ($0.02M)
Other Non-Operating Income / (Expense)
$6.69M $0.06M ($7.09M) $0.17M
Income Tax Provision / (Benefit)
— — $0.00M —
NET INCOME / (NET LOSS)
$5.15M ($4.42M) ($22.39M) ($6.95M)
ASSETS (CURRENT & FIXED)
2025-06-302025-09-302025-12-312026-03-31
Cash and Cash Equivalents
$2.2M$13.3M$4.3M$3.0M
Short-Term Marketable Investments
$4.6M$3.3M$4.4M$12.1M
Total Liquid Cash Resources
$6.9M$16.6M$8.6M$15.1M
Accounts Receivable, Net
// --// --// --// --
Prepaid Expenses & Other Current Assets
$2.3M$1.0M$6.6M$2.9M
Total Current Assets
$9.2M$17.6M$15.2M$18.0M
Property, Plant and Equipment, Net
$0.3M$0.3M$0.3M$1.0M
Intangibles & Other Non-Current Assets
// --// --// --// --
TOTAL CONSOLIDATED ASSETS
$10.3M$18.7M$16.3M$19.9M
LIABILITIES & STOCKHOLDERS' EQUITY
2025-06-302025-09-302025-12-312026-03-31
Accounts Payable
// --// --$3.3M// --
Accrued Expenses & Clinical Liabilities
// --// --// --// --
Total Current Liabilities
$7.3M$13.6M$12.3M$8.0M
Long-Term Corporate Debt Balances
// --// --// --// --
Deferred Revenue & Collaboration Liabilities
// --// --// --// --
Other Long-Term Obligations
$0.0M$0.0M$0.0M$0.0M
Total Liabilities Block
$7.3M$13.6M$12.3M$8.0M
Total Stockholders' Equity
$3.0M$5.1M$4.0M$12.0M
TOTAL LIABILITIES & EQUITY
$10.3M$18.7M$16.3M$19.9M
HISTORICAL RATIO ANALYSIS
2025-06-302025-09-302025-12-312026-03-31
Current Liquidity Ratio
1.26x 1.29x 1.23x 2.27x
R&D Expenditure Flow
$3.0M$5.4M$8.4M$2.9M
Net Income / (Loss)
$5.15M ($4.42M) ($22.39M) ($6.95M)
Depreciation & Amortization
$0.22M $0.30M $0.45M $0.10M
Stock-Based Compensation
$0.30M $0.83M $1.54M $1.02M
Change in Accounts Receivable
— — — —
Change in Prepaid Assets / Expenses
— — — —
Change in Payables & Clinical Accruals
($5.18M) ($6.31M) ($5.62M) $0.49M
Other Operating Source / (Use) Changes
($12.46M) ($4.91M) $5.25M ($0.90M)
Net Cash from Operating Activities
($11.97M) ($14.52M) ($20.77M) ($6.24M)
INVESTING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Capital Expenditures (CapEx)
($0.01M) ($0.04M) ($0.07M) ($0.82M)
Purchases of Marketable Securities
— — — —
Maturities & Sales of Investments
— — — —
Net Cash from Investing Activities
($1.07M) $0.22M ($0.85M) ($8.53M)
FINANCING ACTIVITIES
2025-06-302025-09-302025-12-312026-03-31
Proceeds from Issuing Debt Instruments
— — — —
Repayments of Debt / Leases
— — — —
Proceeds from Issuing Stock / ATM Options
$2.79M $19.61M $22.61M —
Net Cash from Financing Activities
$15.20M $27.51M $30.31M $9.04M
NET CONSOLIDATED CHANGE IN CASH
$2.16M $13.21M $8.68M ($5.74M)
Clinical Trials Registry
No active clinical trials detected in data stream.